De­spite CD­MO head­winds, Sam­sung Bio re­ports 2023 rev­enue jump and pre­dicts even more gains this year

Sam­sung Bi­o­log­ics said on Wednes­day that it de­liv­ered “ex­cep­tion­al” rev­enue growth in 2023 and pre­dicts an in­crease this year, which coun­ters mut­ed re­ports by oth­er CD­MOs due to last year’s biotech fund­ing slump.

The Ko­re­an CD­MO said it gen­er­at­ed a rev­enue of KRW 3.69 tril­lion ($2.8 bil­lion) in 2023, re­flect­ing a 23.1% in­crease from the pre­vi­ous year. It gen­er­at­ed KRW 1.07 tril­lion ($804.4 mil­lion) in rev­enue in the fourth quar­ter of last year, mark­ing an 11.2% growth from KRW 965.5 bil­lion ($725.9 mil­lion) re­port­ed in the same pe­ri­od in 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER